Drug:
Reaction: THERAPY INTERRUPTED
20250101 - 20251231
No. 901 - 1000
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 901 | 25031086 |
44 | 2 | |
Tinea infection, Cestode infection, Therapy interrupted, |
||||
BIMEKIZUMAB, LEVOTHYROXINE, METHYLPHENIDATE, METHYLPHENIDATE HYDROCHLORIDE, GABAPENTIN, ESCITALOPRAM, |
||||
| 902 | 25031100 |
60 | 2 | |
Sinusitis, Therapy interrupted, |
||||
TOFACITINIB, |
||||
| 903 | 25031119 |
77 | 1 | |
Pain, Infection, Eye disorder, Fluid retention, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, ETANERCEPT, |
||||
| 904 | 25031155 |
77 | 2 | |
Influenza, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 905 | 25031202 |
65 | 2 | |
Sinusitis, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 906 | 25031211 |
82 | 2 | |
Bronchitis, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 907 | 25031347 |
78 | 2 | |
Arrhythmia, Atrioventricular block, Cardiac arrest, Therapy interrupted, |
||||
TECLISTAMAB, HUMAN IMMUNOGLOBULIN G, |
||||
| 908 | 25015430 |
IT |
1 | |
Sepsis, Incorrect route of product administration, Therapy interrupted, |
||||
AVACOPAN, AVACOPAN, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 909 | 25016721 |
US |
77 | 2 |
Choking, Stridor, Paraesthesia oral, Sputum retention, Sinusitis, Secretion discharge, Condition aggravated, Sputum discoloured, Dry skin, Insomnia, Rhinorrhoea, Dysgeusia, Wheezing, Feeling abnormal, Vertigo, Cough, Dysphonia, Aphonia, Productive cough, Oral candidiasis, Dizziness, Dyspnoea, Off label use, Therapy interrupted, |
||||
AMIKACIN, AMIKACIN, AMIKACIN, AMIKACIN, SODIUM CHLORIDE, SODIUM CHLORIDE INJECTION, SODIUM CHLORIDE TABLET, NORMAL SALT TABLETS, ALBUTEROL SULFATE, ALBUTEROL, |
||||
| 910 | 25017378 |
US |
55 | 2 |
Device difficult to use, Therapy interrupted, Pain, |
||||
ETANERCEPT, |
||||
| 911 | 25017468 |
71 | 1 | |
Tooth infection, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 912 | 25017490 |
61 | 2 | |
Pneumonia, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 913 | 25017495 |
67 | 2 | |
Illness, Therapy interrupted, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 914 | 25017497 |
65 | 2 | |
Cough, Medication error, Therapy interrupted, |
||||
UPADACITINIB, UPADACITINIB, UPADACITINIB, |
||||
| 915 | 25017541 |
US |
||
Dysarthria, Confusional state, Dizziness, Therapy interrupted, |
||||
RELUGOLIX, |
||||
| 916 | 25017578 |
US |
68 | 1 |
Rheumatoid arthritis, Therapy interrupted, Therapeutic product effect incomplete, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 917 | 25017594 |
BR |
2 | |
Surgery, Myocardial infarction, Renal stone removal, Nephrolithiasis, Product availability issue, Therapy interrupted, |
||||
ROTIGOTINE, ROTIGOTINE, ROTIGOTINE, ROTIGOTINE, |
||||
| 918 | 25017666 |
SA |
47 | 1 |
Depression, Therapy interrupted, |
||||
EVOLOCUMAB, |
||||
| 919 | 25017676 |
US |
1 | |
Cystic fibrosis lung, Therapy interrupted, Off label use, Product administered to patient of inappropriate age, |
||||
AMIKACIN, |
||||
| 920 | 25018078 |
US |
85 | 1 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 921 | 25018079 |
US |
52 | 2 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 922 | 25019062 |
US |
61 | 2 |
Stevens-Johnson syndrome, Cataract, COVID-19, Migraine, Arthritis, Device difficult to use, Drug dose omission by device, Injection site haemorrhage, Injection site pain, Therapeutic response shortened, Therapy interrupted, Wrong technique in product usage process, Injection site urticaria, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, SUMATRIPTAN, ONABOTULINUMTOXINA, |
||||
| 923 | 25019166 |
US |
2 | |
Screaming, Regressive behaviour, Therapy interrupted, |
||||
TROFINETIDE, |
||||
| 924 | 25019263 |
2 | ||
Syncope, Dizziness, Haemorrhage, Blood pressure abnormal, Therapy interrupted, |
||||
MACITENTAN, RIOCIGUAT, SELEXIPAG, SOTATERCEPT-CSRK, TREPROSTINIL, |
||||
| 925 | 25019284 |
2 | ||
Syncope, Dizziness, Haemorrhage, Therapy interrupted, Blood pressure abnormal, |
||||
SOTATERCEPT-CSRK, SELEXIPAG, RIOCIGUAT, MACITENTAN, TREPROSTINIL, |
||||
| 926 | 25019291 |
54 | 1 | |
Hepatitis A, Asthma, Inappropriate schedule of product administration, Therapy interrupted, |
||||
TEZEPELUMAB-EKKO, |
||||
| 927 | 25019689 |
US |
32 | 2 |
Illness, Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 928 | 25019690 |
US |
22 | 2 |
Treatment noncompliance, Therapy interrupted, |
||||
ISOTRETINOIN, |
||||
| 929 | 25019849 |
US |
58 | 1 |
Psoriatic arthropathy, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 930 | 25020008 |
BR |
1 | |
Parkinson^s disease, Product availability issue, Therapy interrupted, |
||||
ROTIGOTINE, |
||||
| 931 | 25020872 |
US |
81 | 1 |
Therapy interrupted, Inability to afford medication, |
||||
APIXABAN, TAFAMIDIS, ENALAPRIL, FUROSEMIDE, METOPROLOL TARTRATE, METOPROLOL, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, DULOXETINE HYDROCHLORIDE, DULOXETINE, DULOXETINE HYDROCHLORIDE, DULOXETINE, |
||||
| 932 | 25022662 |
79 | 2 | |
Haematemesis, Anticoagulation drug level above therapeutic, Anaemia, Hypotension, Therapy interrupted, |
||||
RIOCIGUAT, WARFARIN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, PANTOPRAZOLE, ROSUVASTATIN, MONTELUKAST, ALBUTEROL SULFATE, FLUTICASONE PROPIONATE AND SALMETEROL, |
||||
| 933 | 25022668 |
2 | ||
Fatigue, Syncope, Dizziness, Pulmonary hypertension, Therapy interrupted, |
||||
SOTATERCEPT-CSRK, MACITENTAN, RIOCIGUAT, SELEXIPAG, |
||||
| 934 | 25022741 |
57 | 2 | |
Cholelithiasis, Therapy interrupted, |
||||
SECUKINUMAB, |
||||
| 935 | 25022758 |
27 | 1 | |
Illness, Therapy interrupted, |
||||
IXEKIZUMAB, |
||||
| 936 | 25022767 |
85 | 2 | |
Nasopharyngitis, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 937 | 25022771 |
38 | 2 | |
Influenza, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 938 | 25022772 |
71 | 2 | |
Cardiac operation, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 939 | 25022963 |
2 | ||
Fatigue, Syncope, Dizziness, Therapy interrupted, |
||||
MACITENTAN, SELEXIPAG, RIOCIGUAT, SOTATERCEPT-CSRK, TREPROSTINIL, |
||||
| 940 | 25023330 |
|||
Renal failure, Therapy interrupted, |
||||
CLONIDINE, |
||||
| 941 | 25023508 |
82 | 1 | |
International normalised ratio increased, Ischaemic cerebral infarction, Basal ganglia haemorrhage, Vascular malformation, Therapy interrupted, |
||||
WARFARIN, |
||||
| 942 | 25011121 |
US |
62 | 2 |
Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 943 | 25011183 |
US |
65 | 2 |
Device difficult to use, Drug dose omission by device, Product communication issue, Therapy interrupted, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 944 | 25011525 |
US |
2 | |
Multiple sclerosis relapse, Therapy interrupted, Insurance issue, Off label use, |
||||
INTERFERON BETA-1A, |
||||
| 945 | 25011882 |
2 | ||
Crying, Product use issue, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 946 | 25011891 |
2 | ||
Flushing, Urticaria, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 947 | 25011910 |
US |
54 | 1 |
Psoriasis, Therapy interrupted, |
||||
APREMILAST, |
||||
| 948 | 25012036 |
US |
||
Therapy interrupted, |
||||
CARFILZOMIB, |
||||
| 949 | 25012087 |
US |
47 | 2 |
Rheumatoid arthritis, Bronchiolitis, Immunosuppression, Pulmonary embolism, Hypothyroidism, Seizure like phenomena, Sinus disorder, Nasal disorder, Asthma, Psoriasis, Anxiety, Fibromyalgia, Depression, Diarrhoea, Therapy interrupted, Dysphagia, Restrictive pulmonary disease, Cough, Hyperparathyroidism, Spinal osteoarthritis, Chronic gastritis, Pain, Obesity, Thrombocytosis, Apathy, Central pain syndrome, Intervertebral disc degeneration, Gastrooesophageal reflux disease, Influenza, Gastrointestinal disorder, Swelling, Rash, Urticaria, Restless legs syndrome, Blood iron decreased, |
||||
APREMILAST, APREMILAST, APREMILAST, ETANERCEPT, RITUXIMAB, ALBUTEROL SULFATE, ALBUTEROL SULFATE, AMOXICILLIN AND CLAVULANATE POTASSIUM, BETAMETHASONE DIPROPIONATE, CARBAMIDE PEROXIDE, ERGOCALCIFEROL, ERGOCALCIFEROL, ESOMEPRAZOLE MAGNESIUM, FAMOTIDINE, FLUCONAZOLE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, TRIPROLIDINE HCL, ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, PHENYLEPHRINE HCL, METHOCARBAMOL, METOPROLOL SUCCINATE, MONTELUKAST SODIUM, NALTREXONE, TOPIRAMATE, SARILUMAB, METHOTREXATE SODIUM, TOFACITINIB, ABATACEPT, GOLIMUMAB, |
||||
| 950 | 25012408 |
|||
Suicidal ideation, Loss of therapeutic response, Depression, Insurance issue, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 951 | 25012415 |
44 | 1 | |
Suicidal ideation, Depression, Agitation, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, AMLODIPINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, DIHYDROERGOTAMINE MESYLATE, CLINDAMYCIN PHOSPHATE, CLINDAMYCIN, |
||||
| 952 | 25012575 |
46 | 2 | |
Withdrawal syndrome, Negative thoughts, Indifference, Decreased activity, Mood altered, Insomnia, Therapy interrupted, Product use issue, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, QUETIAPINE, LITHIUM, LITHIUM BROMATUM, LITHIUM, LITHIUM BROMATUM, |
||||
| 953 | 25012576 |
37 | 2 | |
Loss of personal independence in daily activities, Withdrawal syndrome, Headache, Dizziness, Fatigue, Depression, Anxiety, Insurance issue, Therapy interrupted, Product use issue, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE, DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE SULFATE AND AMPHETAMINE ASPARTATE, CEPHALEXIN, |
||||
| 954 | 25012581 |
41 | 2 | |
Malaise, Feeling abnormal, Depressed mood, Anxiety, Inappropriate schedule of product administration, Drug dose titration not performed, Drug delivery system issue, Therapy interrupted, Product use issue, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 955 | 25012582 |
39 | 2 | |
Withdrawal syndrome, Condition aggravated, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 956 | 25012590 |
|||
Feeling abnormal, Headache, Disturbance in attention, Euphoric mood, Anxiety, Depression, Product use issue, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 957 | 25012602 |
23 | 1 | |
Attention deficit hyperactivity disorder, Product use issue, Therapy interrupted, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 958 | 25012653 |
US |
74 | 2 |
Insurance issue, Therapy interrupted, Off label use, |
||||
LENALIDOMIDE, |
||||
| 959 | 25012753 |
34 | 2 | |
Electric shock sensation, Anxiety, Hyperhidrosis, Agitation, Fatigue, Myalgia, Product use issue, Therapy interrupted, Drug dose titration not performed, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, METHYLPHENIDATE HYDROCHLORIDE, |
||||
| 960 | 25012772 |
66 | 2 | |
Feeling hot, Headache, Hyperhidrosis, Depressed mood, Product use issue, Therapy interrupted, Insurance issue, Inappropriate schedule of product administration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, ADALIMUMAB, ADALIMUMAB, LEFLUNOMIDE, |
||||
| 961 | 25012827 |
US |
||
Incorrect dose administered, Off label use, Product dose omission issue, Therapy interrupted, |
||||
RELUGOLIX, RELUGOLIX, CIPROFLOXACIN HYDROCHLORIDE AND HYDROCORTISONE, CIPROFLOXACIN HYDROCHLORIDE, CIPROFLOXACIN, |
||||
| 962 | 25012881 |
72 | 2 | |
Urinary tract infection, Ear infection, Therapy interrupted, |
||||
SECUKINUMAB, |
||||
| 963 | 25012898 |
39 | 2 | |
Malaise, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 964 | 25012939 |
52 | 2 | |
Emergency care, Malaise, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 965 | 25012954 |
66 | 2 | |
Nasopharyngitis, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 966 | 25012982 |
40 | 2 | |
Illness, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 967 | 25013035 |
JP |
||
B precursor type acute leukaemia, Death, Optic neuritis, Encephalopathy, Liver disorder, Full blood count decreased, Therapy interrupted, Blood pressure decreased, Rash, Pyrexia, Therapeutic product effect incomplete, |
||||
BLINATUMOMAB, BLINATUMOMAB, |
||||
| 968 | 25013138 |
US |
2 | |
Somnolence, Intentional dose omission, Therapy interrupted, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 969 | 25013165 |
2 | ||
Feeling abnormal, Emotional disorder, Irritability, Therapy interrupted, Product availability issue, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, LUMATEPERONE, |
||||
| 970 | 25013178 |
40 | 1 | |
Malaise, Discomfort, Nausea, Product use issue, Therapy interrupted, Incorrect dose administered, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 971 | 25013210 |
51 | 2 | |
Feeling abnormal, Therapeutic response unexpected, Product use issue, Therapy interrupted, Insurance issue, |
||||
DEXTROMETHORPHAN HYDROBROMIDE, BUPROPION HYDROCHLORIDE, |
||||
| 972 | 25013283 |
US |
67 | 2 |
Product availability issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 973 | 25013555 |
50 | 2 | |
Therapy interrupted, Insomnia, |
||||
OSELTAMIVIR PHOSPHATE, OSELTAMIVIR ACID, OSELTAMIVIR, LAMOTRIGINE, LAMOTRIGINE EXTENDED-RELEASE, LAMOTRIGINE CHEWABLE DISPERSIBLE, LAMOTIRIGINE, SERTRALINE, GABAPENTIN, HYDROXYZINE, |
||||
| 974 | 25013671 |
US |
2 | |
Drug ineffective, Inability to afford medication, Insurance issue, Therapy interrupted, |
||||
LEVETIRACETAM, LEVETIRACETAM, LEVETIRACETAM ORAL, LEVETIRACETAM INJECTION, LEVETIRACETAM IN SODIUM CHLORIDE, |
||||
| 975 | 25013685 |
US |
1 | |
Dysphemia, Therapy interrupted, Insurance issue, |
||||
LEVETIRACETAM, |
||||
| 976 | 25013731 |
US |
2 | |
Insurance issue, Therapy interrupted, |
||||
LEVETIRACETAM, OXCARBAZEPINE, LAMOTRIGINE, |
||||
| 977 | 25013847 |
US |
76 | 1 |
Dementia, Therapy interrupted, Product availability issue, Product use in unapproved indication, |
||||
BRIVARACETAM, |
||||
| 978 | 25014088 |
US |
2 | |
Myelin oligodendrocyte glycoprotein antibody-associated disease, Visual impairment, Condition aggravated, Loss of personal independence in daily activities, Therapy interrupted, Product administered to patient of inappropriate age, |
||||
ABALOPARATIDE, |
||||
| 979 | 25014230 |
US |
66 | 2 |
Product dose omission issue, Diabetes mellitus, Fatigue, Diarrhoea, Bronchitis, Therapy interrupted, |
||||
| 980 | 25014242 |
US |
75 | 2 |
Psoriasis, Therapy interrupted, |
||||
APREMILAST, AMLODIPINE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, CITALOPRAM, CITALOPRAM HYDROBROMIDE, DIVALPROEX SODIUM, FOLIC ACID, FUROSEMIDE, LEVOTHYROXINE, LORAZEPAM, LOSARTAN, MIRTAZAPINE, PANTOPRAZOLE, PERPHENAZINE, ERGOCALCIFEROL, |
||||
| 981 | 25014244 |
2 | ||
Fluid retention, Angina pectoris, Pain in jaw, Therapy interrupted, |
||||
AMBRISENTAN, AMBRISENTAN, AMBRISENTAN, FUROSEMIDE, |
||||
| 982 | 25014332 |
NO |
2 | |
Plasma cell myeloma, Product packaging issue, Therapy interrupted, |
||||
DARBEPOETIN ALFA, DARBEPOETIN ALFA, |
||||
| 983 | 25014459 |
US |
54 | 2 |
Hepatic encephalopathy, Disease recurrence, Therapy interrupted, Insurance issue, Inability to afford medication, |
||||
RIFAXIMIN, LACTULOSE, |
||||
| 984 | 25014482 |
1 | ||
Pyrexia, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 985 | 25014924 |
35 | 2 | |
Kidney infection, Therapy interrupted, Optic neuritis, Treatment noncompliance, |
||||
UPADACITINIB, |
||||
| 986 | 25015194 |
US |
69 | 2 |
Muscle spasms, Diarrhoea, Photophobia, Therapy interrupted, |
||||
TEPROTUMUMAB, |
||||
| 987 | 25015273 |
US |
65 | 2 |
Wrong technique in product usage process, Accidental exposure to product, Drug dose omission by device, Device use error, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, |
||||
| 988 | 25017236 |
49 | 1 | |
Dizziness, Therapy interrupted, |
||||
AMBRISENTAN, DIGOXIN, FUROSEMIDE, GABAPENTIN, SILDENAFIL CITRATE, SILDENAFIL, SILDENAFIL POWDER,, |
||||
| 989 | 25017311 |
52 | 2 | |
Illness, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 990 | 25017370 |
53 | 1 | |
Bronchitis, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 991 | 25017431 |
51 | 1 | |
Cough, Therapy interrupted, |
||||
ADALIMUMAB, |
||||
| 992 | 25017436 |
1 | ||
Hernia, Therapy interrupted, |
||||
LENALIDOMIDE, APIXABAN, DAPAGLIFLOZIN, |
||||
| 993 | 25017443 |
1 | ||
Plasma cell myeloma, Stem cell transplant, Therapy interrupted, |
||||
RISANKIZUMAB-RZAA, |
||||
| 994 | 25017457 |
55 | 1 | |
Illness, Therapy interrupted, |
||||
APREMILAST, |
||||
| 995 | 25017460 |
72 | 2 | |
Illness, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 996 | 25017464 |
77 | 2 | |
COVID-19, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 997 | 25017472 |
48 | 2 | |
Chest pain, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 998 | 25006927 |
CO |
48 | 1 |
Skin abrasion, Arthralgia, Dermatitis atopic, Fibula fracture, Road traffic accident, Therapy interrupted, Surgery, Product dispensing issue, |
||||
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE, CERTOLIZUMAB PEGOL, METHOTREXATE, METHOTREXATE SODIUM, LOSARTAN, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 999 | 25007018 |
US |
50 | 2 |
Device difficult to use, Therapy interrupted, Product communication issue, Wrong technique in product usage process, Product administration error, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 1000 | 25007039 |
US |
68 | 2 |
Upper respiratory tract infection, Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28